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1 	 | 	 INTRODUCTION
Exposure	 to	 antiseizure	 medication	 (ASM)	 during	 preg-
nancy	 is	 associated	 with	 an	 increased	 risk	 of	 congenital	





examining	 the	 interplay	 between	 folate	 metabolism	 and	
ASM	 use	 are	 needed	 in	 pregnant	 women.	 Women	 with	
epilepsy	using	ASMs	are	often	recommended	a	high	dose	
of	 folic	 acid	 supplement	 during	 pregnancy.1,3,11	 Studies	
of	nonepilepsy	populations	show	that	excessive	folic	acid	
supplementation	 results	 in	 plasma	 accumulation	 of	 un-







and	 pyridoxine	 (vitamin	 B6).5,7,17,18	 Riboflavin	 and	 pyri-
doxine	act	 in	close	 interaction	with	folate	 in	one-	carbon	
metabolism,	 representing	 metabolic	 pathways	 funda-
mental	for	normal	fetal	development.9,19 Niacin	(vitamin	
B3)	 plays	 a	 key	 role	 in	 neuronal	 development	 and	 sur-
vival.20  The	 association	 between	 ASM	 use	 and	 vitamin	
B	status	 in	pregnant	women	with	epilepsy	has	not	been	
examined	in	detail.	One	study	reported	an	association	be-










2 	 | 	 MATERIAL­AND­METHODS
2.1	 |	 Study­population
The	 study	 population	 included	 singleton	 pregnancies	 of	
women	 with	 epilepsy	 using	 ASM	 with	 available	 plasma	
samples	 enrolled	 in	 the	 Norwegian	 Mother,	 Father	 and	
Child	Cohort	Study	(MoBa).	MoBa	is	a	population-	based	
pregnancy	 cohort	 study	 conducted	 by	 the	 Norwegian	
Institute	 of	 Public	 Health	 and	 linked	 to	 the	 compulsory	
Medical	Birth	Registry	of	Norway	(MBRN).23	During	the	







rent	 study	 is	 based	 on	 version	 10	 of	 the	 quality-	assured	
MoBa	data	files.
We	 identified	 women	 with	 epilepsy	 based	 on	 self-	





and	 from	 the	MBRN.23	Response	 rates	were	97%	 for	 the	
















5–	8,	 9–	12,	 13+	 (first	 questionnaire)	 and	 for	 gestational	
Key­point
•	 Antiseizure	medication	(ASM)	use	is	associated	
with	 low	 concentrations	 of	 folate	 and	 other	 B	
vitamins	in	nonpregnant	epilepsy	populations
•	 High	ASM	concentrations	correlated	with	high	






low	 riboflavin	 and	 pyridoxine	 status	 in	 preg-
nant	women	with	epilepsy









We	 collected	 information	 on	 folic	 acid	 dose	 from	 97	
of	 227	 pregnancies	 (43%)	 with	 data	 from	 the	 retrospec-
tive	 validation	 questionnaire,25	 as	 this	 information	 was	







We	 analyzed	 plasma	 concentrations	 of	 valproate,	 carba-
mazepine,	 lamotrigine,	 levetiracetam,	 topiramate,	 and	
the	 oxcarbazepine	 monohydroxyderivative	 metabolite.25	
Standardized	 ASM	 concentrations	 were	 calculated	 by	
normalizing	 the	 plasma	 concentrations	 to	 the	 concen-
tration	range	observed	for	that	drug	in	the	present	study	
according	 to	 the	 formula	 100 x (observed concentration	
−	minimum concentration measured for that drug)	/	con-





We	 analyzed	 plasma	 vitamin	 and	 metabolite	 concentra-
tions	 at	 Bevital	 Laboratory,	 Bergen	 (www.bevit	al.no).	
We	 examined	 folate	 status	 by	 analyzing	 the	 biologically	
active	 5-	methyltetrahydrofolate	 (mTHF)	 metabolite,	 the	
mTHF-	derived	 4-	alfa-	hydroxy-	5-	methyltetrahydrofolate	
(hmTHF)	metabolite,	and	 the	 inactive	metabolites	para-	
aminobenzoylglutamate	 (pABG)	 and	 acetamidobenzoyl-
glutamate	(apABG),31	as	well	as	unmetabolized	folic	acid	
(UMFA).31	 UMFA	 values	 below	 the	 limit	 of	 quantifica-
tion	(LOQ,	0.53 nmol/L)31	were	reported	as	0.0 nmol/L.	
Metabolically	active	folate	concentration	was	given	as	the	
sum	 of	 mTHF	 and	 hmTHF	 (“folate”).26,31–	33  We	 calcu-
lated	 the	 ratio	between	 the	active	 (mTHF	plus	hmTHF)	
and	 inactive	 (pABG	plus	apABG)	 folate	metabolites	and	
used	 a	 low	 ratio	 as	 a	 marker	 of	 increased	 folate	 catabo-
lism.	 We	 also	 calculated	 the	 ratio	 between	 UMFA	 and	
metabolically	active	folate	to	better	separate	the	effect	of	
UMFA	from	the	effect	of	folate.31,34
We	 analyzed	 plasma	 riboflavin	 to	 examine	 riboflavin	
status.35  We	 examined	 pyridoxine	 status	 by	 analyzing	






We	 used	 IBM	 SPSS	 Software	 version	 25	 for	 the	 sta-
tistical	 analyses.	 We	 categorized	 the	 pregnancies	 ac-
cording	 to	 ASM	 monotherapy	 and	 ASM	 polytherapy.	
Pregnancies	 where	 none	 of	 the	 reported	 ASMs	 could	
be	detected	were	categorized	 into	a	 separate	group	of	
suspected	 low	 ASM	 adherence	 pregnancies.	 We	 re-
corded	 relevant	 covariates	 from	 the	 questionnaire	 in	
gestational	 weeks	 17–	19,	 and	 from	 the	 MBRN	 strati-
fied	for	ASM	group28,29: maternal	age,	parity,	maternal	
education,	 maternal	 prepregnancy	 body	 mass	 index	
(BMI),	 smoking	 during	 pregnancy,	 unplanned	 preg-
nancy,	epileptic	seizures	during	pregnancy,	and	tonic-	









tion	 and	 low	 number	 of	 pregnancies	 in	 each	 group.	
Adjustment	for	multiple	testing	was	done	by	multiply-
ing	 the	 observed	 p-	value	 by	 the	 number	 of	 compari-
sons	 made	 (Dunn-	Bonferroni	 post	 hoc	 method).	 This	
Bonferroni	 corrected	 p-	value	 was	 considered	 statisti-
cally	significant	when	<0.05.	We	used	Mann-	Whitney	
U	 test	 to	 compare	 vitamin	 and	 metabolite	 concentra-
tions	 between	 supplemented	 and	 nonsupplemented	
pregnancies	and	between	high-	dose	and	low-	dose	folic	
acid	 supplement,	 stratified	 for	ASM	group.	We	exam-
ined	the	associations	between	ASM	concentrations	and	
vitamin	 and	 metabolite	 concentrations	 in	 a	 nonpara-
metric	 correlation	 analysis	 (Spearman	 rank	 correla-
tion).	We	performed	sensitivity	analyses	by	excluding	
supplement	 users	 from	 the	 correlation	 analyses	 for	
riboflavin,	 niacin,	 and	 pyridoxine.	 For	 folate	 status,	
high-	dose	 folic	 acid	 supplement	 users	 were	 excluded,	
because	exclusion	of	nonsupplemented	folic	acid	preg-
nancies	(n	=	13)	was	not	meaningful.






Medical	 Research	 Ethics.	 The	 MoBa	 cohort	 is	 regulated	




3 	 | 	 RESULTS








for	 valproate	 (n	 =	 24),	 lamotrigine	 (n	 =	 65),	 carbamaz-
epine	(n	=	48),	levetiracetam	(n	=	11),	topiramate	(n	=	8),	
and	 oxcarbazepine	 (n	 =	 5);	 one	 polytherapy	 group	 with	
at	 least	one	of	 the	reported	ASMs	detected	 in	plasma	(n	
=	40);	and	one	low-	adherence	group	with	none	of	the	re-
ported	ASMs	detected	in	plasma	(n	=	26)	(Table	1).	Most	




In	 221	 pregnancies	 with	 available	 supplement	 data,	
the	women	reported	any	folic	acid	supplement	use	in	208	
(94%),	 riboflavin	 supplement	 in	 72	 (33%),	 niacin	 in	 45	
(20%),	and	pyridoxine	in	77	pregnancies	(35%)	(Table	1).	
Intake	 was	 reported	 as	≥4–	6	 times	 per	 week	 or	 daily	 in	
≥90%	of	the	pregnancies	for	all	supplements.
Among	 the	 included	pregnancies	 from	 the	 retrospec-
tive	 validation	 survey,	 76	 (33%)	 had	 precise	 information	
on	folic	acid	dose	from	gestational	weeks	−4	to	24.	High-	








The	 low-	adherence	 group	 had	 the	 lowest	 folate	 con-
centrations;	otherwise	there	were	few	differences	in	folate	
between	the	different	ASM	(Table	2).	The	UMFA	concen-
trations	 were	 higher	 in	 mothers	 using	 valproate,	 lamo-
trigine,	carbamazepine,	or	ASM	polytherapy,	respectively,	
compared	to	the	low-	adherence	group	(Table	2).	The	con-
centrations	 of	 the	 inactive	 folate	 metabolites	 and	 ratio	
between	 active	 and	 inactive	 folate	 metabolites	 differed	
between	 individual	 ASMs	 (Table	 2).	 The	 concentrations	
of	 inactive	 folate	 metabolites	 were	 higher	 in	 ASM	 poly-









In	 particular,	 high	 valproate	 concentrations	 cor-
related	 with	 high	 concentrations	 of	 inactive	 folate	
(Figure	 3	 and	 Table	 S2).	 The	 correlation	 strength	 re-
mained	unchanged	after	removing	high-	dose	folic	acid	
users	 (Table	 S2).	 High	 topiramate	 concentrations	 cor-
related	 with	 high	 UMFA	 concentrations,	 but	 the	 cor-
relation	strength	was	reduced	after	removal	of	high-	dose	
supplement	users	(Table	S2).




users	 did	 not	 differ	 in	 ASM	 concentrations	 compared	
to	low-	dose	users	(data	not	shown).	After	stratification	
for	 ASM	 group,	 the	 concentrations	 of	 the	 different	 fo-
late	 metabolites	 in	 high-	dose	 users	 compared	 to	 low-	
dose	users	were	essentially	the	same	across	ASM	groups	
(Figure	S2).
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3.2	 |	 Riboflavin­status­and­association­
with­ASM­concentrations














pyridoxine	 concentration	 did	 not	 differ	 between	 indi-
vidual	ASMs	(Table	2),	but	between	supplement	users	
and	nonusers	(Table	3).	However,	for	individual	ASMs,	
high	 valproate	 concentrations	 correlated	 with	 high	
HKr	 (Figure	 3	 and	 Table	 S2).	 In	 this	 group,	 the	 HKr	
was	higher	than	in	the	other	ASM	groups	(Table	2),	par-





and	 nicotinamide	 (Table	 S2).	 The	 nicotinamide	 concen-
trations	 did	 not	 differ	 between	 different	 ASM	 groups	
(Table	2	and	Table	3).
4 	 | 	 DISCUSSION
In	 this	 cohort	 of	 pregnant	 women	 with	 epilepsy	 using	









The	 median	 folate	 concentration	 was	 lowest	 in	 the	
group	with	low	adherence	to	ASM	therapy	and	probably	
also	 to	 folic	 acid	 supplement	 use.	 Low	 folate	 concentra-
tions	 during	 valproate,	 carbamazepine,	 oxcarbazepine,	
topiramate,6,7	 and	 lamotrigine	 treatment8  have	 been	 re-
ported	in	nonpregnant	epilepsy	populations	compared	to	
controls	without	ASM	use.	Folic	acid	supplement	use	 in	
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10­ |­ ­ ­ HUSEBYE et al.
pregnancy	has	been	associated	with	a	higher	IQ	 in	chil-
dren	 of	 mothers	 taking	 lamotrigine	 or	 carbamazepine	
treatment	particularly.38,39	In	a	study	of	pregnant	women	
with	epilepsy	and	levetiracetam	or	lamotrigine	treatment,	
low	 concentrations	 of	 biologically	 active	 folate	 (mTHF)	
were	 found	 with	 lamotrigine,	 but	 folic	 acid	 supplement	
status	 was	 not	 reported.22	 Lamotrigine	 use	 was	 further-
more	 associated	 with	 changes	 in	 one-	carbon	 metabo-
lism,	with	altered	pathways	involving	folate,	purine,	and	





and	 carbamazepine	 particularly	 influence	 one-	carbon	








tabolites	 and	 a	 lower	 ratio	 between	 active	 and	 inactive	
folate	 metabolites	 in	 women	 using	 valproate,	 carbamaz-
epine,	and	ASM	polytherapy,	compared	to	several	of	the	
other	 ASM	 groups.	 Chronic	 high-	dose	 folic	 acid	 supple-














centrations	 of	 UMFA.	 However,	 studies	 in	 both	 non-
pregnant40	 and	 pregnant34,41	 women	 from	 the	 general	
population	found	that	the	UMFA	concentration	does	not	
depend	 solely	 on	 the	 intake	 of	 folic	 acid,	 and	 suggested	
that	 there	are	mechanisms	by	which	 the	body	adapts	 to	
high	 supplement	 intake,	 thus	 limiting	high	plasma	con-
centrations	 of	 UMFA.	 High	 ASM	 concentrations	 cor-
related	with	high	UMFA	concentrations	in	our	study,	and	







of	 cord	blood	UMFA	and	 increased	 risk	of	autism	spec-












in	 nonpregnant	 epilepsy	 populations.18	 Low	 pyridoxine	
concentrations	during	ASM	use	have	also	been	reported,	
but	less	consistently.5,18,43	Few	studies	have	examined	the	
association	 between	 ASM	 and	 nonfolate	 B	 vitamins	 in	
pregnant	women	with	epilepsy.	Adequate	riboflavin	and	














epilepsy	 in	 Norway.25  Multivitamin	 and	 folic	 acid	 sup-
plement	 users	 are	 overrepresented	 in	 MoBa,	 whereas	
smokers	are	underrepresented.44	Hence,	we	assume	that	
women	 included	 in	 this	 study	 had	 a	 healthier	 lifestyle	
than	 women	 refusing	 inclusion,	 and	 a	 better	 	vitamin  B	
status.	 This	 would	 bias	 our	 results	 towards	 the	 null.	
Limitations	 of	 the	 study	 include	 plasma	 concentrations	











­ ­ ­ |­ 11HUSEBYE et al.
than	 ASM	 treatment	 also	 influence	 the	 vitamin	 status	
during	 pregnancy.	 We	 presented	 standardized	 maternal	
ASM	 concentrations	 in	 addition	 to	 the	 individual	 ASM	
concentrations.	By	using	relative	plasma	concentrations,	
we	adjusted	for	differences	in	pharmacokinetics	between	







In	 conclusion,	 we	 found	 important	 associations	 be-





ASM	 concentrations	 and	 low	 riboflavin	 and	 pyridoxine	
status.	Optimal	concentrations	of	both	these	vitamins	are	
required	for	normal	folate	metabolic	functioning	and	are	
thus	 essential	 for	 normal	 fetal	 development.	 Our	 find-
ings	 provide	 new	 information	 regarding	 the	 association	
between	 ASM	 and	 vitamin	 B	 status	 during	 pregnancy.	
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